Veterinary Aerosol & Bag-on-Valve Manufacturing UK

No. A product intended for use in, on or near animals is not automatically a veterinary medicine. Classification depends on its ingredients, intended purpose, mode of action and, importantly, how the product is named, labelled, described and advertised. A routine grooming spray, coat cleanser or general hygiene product may be non-medicinal when it is genuinely presented for maintaining normal cleanliness or condition in a healthy animal.

However, a product may be treated as a veterinary medicine if it is presented as treating or preventing disease, restoring or modifying physiological functions, relieving symptoms or producing another medicinal effect. This can happen even when the manufacturer did not intend to create a medicine. Claims on packaging, websites, social media, brochures and testimonials can all influence the assessment.

The distinction should therefore be examined before the formula, artwork and marketing strategy are finalised. Brands should define the intended use precisely and review every proposed claim for consistency. Hydrokem can help assess technical feasibility, packaging, compatibility and manufacture, but specialist regulatory advice may also be appropriate where classification is uncertain. Resolving the issue early protects the development budget and reduces the risk of relabelling, reformulation, delayed launch or regulatory intervention after the product has entered the market.

Bag-on-Valve may be selected when a veterinary or animal-care formulation benefits from being physically separated from the propellant. The product is filled into a sealed internal bag, while compressed air or nitrogen surrounds the bag inside the can. Pressing the actuator uses that external pressure to dispense the formulation without the propellant mixing directly with it.

This arrangement can support sensitive formulations, controlled dispensing and effective use through different pack angles. Angled performance can be valuable when applying products to hooves, legs, coats or areas that are difficult to reach while an animal is standing or moving. BoV can also provide high product evacuation and may dispense liquids, gels, creams or selected foams, depending on the valve and actuator system.

It should not be assumed that BoV is automatically superior for every veterinary concept. The correct choice depends on viscosity, desired spray pattern, dose, formula sensitivity, pack size, component availability, production volume and target cost. Compatibility and stability still need to be demonstrated, and the regulatory classification depends on the product’s purpose and claims rather than the packaging format alone. A feasibility review allows the brand and manufacturer to compare BoV with a conventional aerosol using practical technical, commercial and compliance criteria.

UK brands should treat any wording that implies treatment, prevention, cure, relief, physiological modification or a medicinal effect with particular care. For a non-medicinal veterinary product, language that appears commercially attractive may unintentionally cause the product to be regarded as medicinal by presentation. The risk is not limited to explicit statements such as “treats disease”. Words suggesting that a product heals, prevents infection, relieves a recognised condition, promotes physiological improvement or acts as a substitute for a medicine may also create difficulties.

The assessment covers the complete presentation. Product names, pack graphics, instructions, website copy, social media, influencer content, educational articles, before-and-after images and customer testimonials should tell the same compliant story. A disclaimer will not necessarily correct an otherwise medicinal impression, and a claim should not be used simply because a competitor appears to use similar wording.

Brands should begin with a precise description of what the product actually does and the evidence available to support it. Claims can then be written narrowly, accurately and without implying effects that exceed the intended classification. Technical information supplied by a contract manufacturer can help substantiate characteristics such as dispensing format or packaging performance, but responsibility for product presentation normally remains with the business placing the branded product on the market. Regulatory review before artwork approval is far less disruptive than correcting claims after printing or launch.

The testing programme should reflect the formulation, pack format, intended species, application site, product classification and conditions of use. At a minimum, development normally needs to establish that the formula remains compatible with the can, bag, valve, seals, actuator and any other product-contact components. The complete pack should dispense consistently and maintain its integrity throughout the proposed shelf life.

Relevant work may include stability studies, compatibility assessment, leak and pressure checks, discharge-rate measurement, spray-pattern evaluation, dose consistency, foam assessment, clogging checks and product-evacuation testing. Products expected to work sideways or upside down should be assessed in the intended orientations. Veterinary applications may also require consideration of spray noise, application force, droplet characteristics and whether the delivery method creates avoidable stress or exposure for the animal and user.

The final programme can be more extensive for medicinal, sensitive, preservative-free or higher-risk products. Microbiological, toxicological, clinical, efficacy or other specialist evidence may be necessary depending on the regulatory route and claims. Testing should be planned before commercial production because a failed result can require a component change, reformulation or repeat stability work. Hydrokem can coordinate aerosol-pack testing and manufacturing validation, while the brand owner and its regulatory advisers determine the complete evidence package needed for lawful market placement.

There is no single development period for every veterinary aerosol because the timeline depends on whether the project uses an established formula, requires new formulation work, follows a conventional aerosol or Bag-on-Valve route, and is medicinal or non-medicinal. A straightforward non-medicinal product using proven components may progress more quickly than a novel, sensitive or regulated concept requiring extended evidence and formal authorisation.

The main stages include defining intended use, resolving classification, confirming claims, establishing technical feasibility, developing or transferring the formulation, selecting components, producing samples, completing compatibility and stability work, approving artwork and arranging commercial production. Custom components, specialist actuators and printed cans can add procurement lead time. Testing must also run for long enough to provide meaningful evidence, so it should not be treated as a final administrative step.

Projects are usually delayed when key decisions are left unresolved. Examples include changing claims after artwork has been prepared, selecting packaging before formula compatibility is known, or discovering late that the proposed presentation may imply a veterinary medicinal purpose. The most reliable way to control timing is to involve manufacturing and regulatory specialists at the briefing stage. Hydrokem can then identify technical dependencies, component lead times and production requirements early, creating a realistic development plan rather than promising a launch date that ignores validation and compliance.